Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1858 ARTÍCULOS , VIENDO DEL 1306 AL 1320

Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease

Cantero JL, Atienza M, Lage C, Zaborszky L, Vilaplana E, Lopez-Garcia S, Pozueta A, Rodriguez-Rodriguez E, Blesa R, Alcolea D, Lleo A, Sanchez-Juan P, Fortea J; Alzheimer’s Disease Neuroimaging Initiative.

Cereb Cortex. 2020 Apr 14;30(4):2083-2098. doi: 10.1093/cercor/bhz224.

Current opinion neurology: visual pathway biomarkers in Alzheimer's disease

Van Stavern GP.

Curr Opin Neurol. 2020 Feb;33(1):79-86. doi: 10.1097/WCO.0000000000000788.

Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice

Shaw LM, Korecka M, Figurski M, Toledo J, Irwin D, Hee Kang J, Trojanowski JQ.

J Appl Lab Med. 2020 Jan 1;5(1):183-193. doi: 10.1373/jalm.2019.029587.

Role of Post-translational Modifications in Alzheimer's Disease

Ramesh M, Gopinath P, Govindaraju T.

Chembiochem. 2020 Apr 17;21(8):1052-1079. doi: 10.1002/cbic.201900573. Epub 2020 Jan 30.

Peripheral inflammatory biomarkers in Alzheimer's disease: a brief review

Park JC, Han SH, Mook-Jung I.

BMB Rep. 2020 Jan;53(1):10-19. doi: 10.5483/BMBRep.2020.53.1.309.

Developing robust biomarkers for vascular cognitive disorders: adding 'V' to the AT(N) research framework

Sachdev PS.

Curr Opin Psychiatry. 2020 Mar;33(2):148-155. doi: 10.1097/YCO.0000000000000577.

[Current Clinical Trials in the Treatment of Alzheimer's Disease]

Tamaoka A.

Brain Nerve. 2020 Jan;72(1):23-34. doi: 10.11477/mf.1416201475.

Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward

Alber J, Goldfarb D, Thompson LI, Arthur E, Hernandez K, Cheng D, DeBuc DC, Cordeiro F, Provetti-Cunha L, den Haan J, Van Stavern GP, Salloway SP, Sinoff S, Snyder PJ.

Alzheimers Dement. 2020 Jan;16(1):229-243. doi: 10.1002/alz.12006.

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease

Wattmo C, Blennow K, Hansson O.

BMC Neurol. 2020 Jan 9;20(1):10. doi: 10.1186/s12883-019-1591-0.

Blood-based Biomarkers of Alzheimer's Disease: The Long and Winding Road

Manzine PR, Vatanabe IP, Peron R, Grigoli MM, Pedroso RV, Nascimento CMC, Cominetti MR.

Curr Pharm Des. 2020;26(12):1300-1315. doi: 10.2174/1381612826666200114105515.

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort

Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Baker S, Buckley NJ, Ten Kate M, Scheltens P, Teunissen CE, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lléo A, Sala I, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Legido-Quigley C, Bertram L, Barkhof F, Zetterberg H, Morgan BP, Streffer J, Visser PJ, Lovestone S.

J Alzheimers Dis. 2020;74(1):213-225. doi: 10.3233/JAD-190434.

Editorial: Searching for the Holy Grail Will Need Biomarkers

Ramirez A.

J Prev Alzheimers Dis. 2020;7(1):4-6. doi: 10.14283/jpad.2020.2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias